Linked Data API

Show Search Form

Search Results

224734
registered interest false more like this
date less than 2015-03-03more like thismore than 2015-03-03
answering body
Department of Health more like this
answering dept id 17 more like this
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Health Services: Greater Manchester more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, what assessment he has made of the potential effect of devolution of spending to Greater Manchester on (a) patients who live outside the Greater Manchester area but who are registered with a GP there and (b) patients who wish to receive treatment at a hospital in Greater Manchester but who live outside the area. more like this
tabling member constituency Warrington North more like this
tabling member printed
Helen Jones more like this
uin 226124 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2015-03-06more like thismore than 2015-03-06
answer text <p>This is a historic partnership between local organisations in Greater Manchester (GM), with general practitioners as clinical leaders working with elected leaders to improve services for people living in the area.</p><p> </p><p> </p><p> </p><p>The National Health Service bodies involved, including NHS England and the relevant clinical commissioning groups, will remain statutorily accountable for the exercise of their functions. GM will work collaboratively with local non-GM bodies and take into account the impact of GM decisions upon non-GM bodies and their communities.</p><p> </p><p> </p><p> </p><p>The fundamental national policies including Choice, inspection regimes, guidance and regulations will continue to apply to GM but, in line with the Five Year Forward View published by NHS England, GM will exercise greater freedom in how they are implemented so that local services better reflect the priorities of local patients and service users.</p><p> </p> more like this
answering member constituency Mid Norfolk more like this
answering member printed George Freeman remove filter
question first answered
less than 2015-03-06T14:37:14.263Zmore like thismore than 2015-03-06T14:37:14.263Z
answering member
4020
label Biography information for George Freeman more like this
tabling member
432
label Biography information for Helen Jones more like this
224735
registered interest false more like this
date less than 2015-03-03more like thismore than 2015-03-03
answering body
Department of Health more like this
answering dept id 17 more like this
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Clinical Commissioning Groups: Cumbria more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, what funding (a) in total and (b) per capita has been allocated for Cumbria Clinical Commissioning Group for each year from 2013-14 to 2019-20. more like this
tabling member constituency Copeland more like this
tabling member printed
Mr Jamie Reed more like this
uin 226114 more like this
answer
answer
is ministerial correction true more like this
date of answer less than 2015-03-06more like thismore than 2015-03-06
answer text <p>Clinical commissioning group (CCG) funding has not been decided beyond 2015/16. Notified revenue allocations and per capita allocations for Cumbria CCG are:</p><p> </p><p> </p><p> </p><table><tbody><tr><td><p>Year</p></td><td><p>Allocation £000</p></td><td><p>Per capita £</p></td></tr><tr><td><p>2013/14</p></td><td><p><del class="ministerial">692,122</del></p><p><ins class="ministerial">663,133</ins></p></td><td><p><del class="ministerial">1,330</del></p><p><ins class="ministerial">1,274</ins></p></td></tr><tr><td><p>2014/15</p></td><td><p>677,324</p></td><td><p>1,299</p></td></tr><tr><td><p>2015/16</p></td><td><p>685,654</p></td><td><p>1,313</p></td></tr></tbody></table><p> </p><p> </p><p> </p><p>These figures exclude running cost and Better Care Fund allocations.</p><p> </p> more like this
answering member constituency Mid Norfolk more like this
answering member printed George Freeman remove filter
question first answered
remove maximum value filtermore like thismore than 2015-03-06T14:39:07.327Z
question first ministerially corrected
less than 2015-03-19T18:02:16.817Zmore like thismore than 2015-03-19T18:02:16.817Z
answering member
4020
label Biography information for George Freeman more like this
previous answer version
48371
answering member constituency Mid Norfolk more like this
answering member printed George Freeman more like this
answering member
4020
label Biography information for George Freeman more like this
tabling member
1503
label Biography information for Mr Jamie Reed more like this
224154
registered interest false more like this
date less than 2015-02-27more like thismore than 2015-02-27
answering body
Department of Health more like this
answering dept id 17 more like this
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Epilepsy more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, how much public money has been invested into development of new drugs and treatments for epilepsy in each of the last five years. more like this
tabling member constituency Leicester West more like this
tabling member printed
Liz Kendall more like this
uin 225706 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2015-03-04more like thismore than 2015-03-04
answer text <p>The following table shows estimated expenditure on epilepsy research and development by the National Institute for Health (NIHR) through its research programmes, research centres and units and research fellowships.</p><p> </p><p> </p><p> </p><p><em>£ million</em></p><p> </p><table><tbody><tr><td><p> </p></td><td><p>2009/10</p></td><td><p>2010/11</p></td><td><p>2011/12</p></td><td><p>2012/13</p></td><td><p>2013/14</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.8</p></td><td><p>1.0</p></td><td><p>1.3</p></td><td><p>2.7</p></td><td><p>3.1</p></td></tr></tbody></table><p> </p><p> </p><p> </p><p>Total spend by the NIHR on epilepsy is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on this condition cannot be disaggregated from total CRN expenditure.</p><p> </p><p> </p><p> </p><p>The following table shows estimated expenditure on research on epilepsy by the Research Councils and Innovate UK.</p><p> </p><p> </p><p> </p><p><em>£ million</em></p><p> </p><table><tbody><tr><td><p> </p></td><td><p>2009/10</p></td><td><p>2010/11</p></td><td><p>2011/12</p></td><td><p>2012/13</p></td><td><p>2013/14</p></td></tr><tr><td><p>Research Councils and Innovate UK</p></td><td><p>4.2</p></td><td><p>3.5</p></td><td><p>2.0</p></td><td><p>2.3</p></td><td><p>3.1</p></td></tr></tbody></table><p> </p><p> </p><p> </p><p>In addition to research directly relating to epilepsy, the Medical Research Council also supports a broad portfolio of research that aims to improve our understanding of the underlying mechanisms of neuroscience and neurological conditions including epilepsy.</p><p> </p><p> </p><p> </p><p>The following table shows estimated expenditure on development of new drugs and treatments for epilepsy by the Research Councils and Innovate UK.</p><p> </p><p> </p><p> </p><p><em>£ million</em></p><p> </p><table><tbody><tr><td><p> </p></td><td><p>2009/10</p></td><td><p>2010/11</p></td><td><p>2011/12</p></td><td><p>2012/13</p></td><td><p>2013/14</p></td></tr><tr><td><p>Research Councils and Innovate UK</p></td><td><p>0.1</p></td><td><p>0.2</p></td><td><p>0.3</p></td><td><p>0.3</p></td><td><p>0.4</p></td></tr></tbody></table><p> </p><p> </p><p> </p>
answering member constituency Mid Norfolk more like this
answering member printed George Freeman remove filter
grouped question UIN 225699 more like this
question first answered
less than 2015-03-04T17:25:17.93Zmore like thismore than 2015-03-04T17:25:17.93Z
answering member
4020
label Biography information for George Freeman more like this
tabling member
4026
label Biography information for Liz Kendall more like this
224161
registered interest false more like this
date less than 2015-02-27more like thismore than 2015-02-27
answering body
Department of Health more like this
answering dept id 17 more like this
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Epilepsy more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, how much public money has been granted into research into epilepsy in each of the last five years. more like this
tabling member constituency Leicester West more like this
tabling member printed
Liz Kendall more like this
uin 225699 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2015-03-04more like thismore than 2015-03-04
answer text <p>The following table shows estimated expenditure on epilepsy research and development by the National Institute for Health (NIHR) through its research programmes, research centres and units and research fellowships.</p><p> </p><p> </p><p> </p><p><em>£ million</em></p><p> </p><table><tbody><tr><td><p> </p></td><td><p>2009/10</p></td><td><p>2010/11</p></td><td><p>2011/12</p></td><td><p>2012/13</p></td><td><p>2013/14</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.8</p></td><td><p>1.0</p></td><td><p>1.3</p></td><td><p>2.7</p></td><td><p>3.1</p></td></tr></tbody></table><p> </p><p> </p><p> </p><p>Total spend by the NIHR on epilepsy is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on this condition cannot be disaggregated from total CRN expenditure.</p><p> </p><p> </p><p> </p><p>The following table shows estimated expenditure on research on epilepsy by the Research Councils and Innovate UK.</p><p> </p><p> </p><p> </p><p><em>£ million</em></p><p> </p><table><tbody><tr><td><p> </p></td><td><p>2009/10</p></td><td><p>2010/11</p></td><td><p>2011/12</p></td><td><p>2012/13</p></td><td><p>2013/14</p></td></tr><tr><td><p>Research Councils and Innovate UK</p></td><td><p>4.2</p></td><td><p>3.5</p></td><td><p>2.0</p></td><td><p>2.3</p></td><td><p>3.1</p></td></tr></tbody></table><p> </p><p> </p><p> </p><p>In addition to research directly relating to epilepsy, the Medical Research Council also supports a broad portfolio of research that aims to improve our understanding of the underlying mechanisms of neuroscience and neurological conditions including epilepsy.</p><p> </p><p> </p><p> </p><p>The following table shows estimated expenditure on development of new drugs and treatments for epilepsy by the Research Councils and Innovate UK.</p><p> </p><p> </p><p> </p><p><em>£ million</em></p><p> </p><table><tbody><tr><td><p> </p></td><td><p>2009/10</p></td><td><p>2010/11</p></td><td><p>2011/12</p></td><td><p>2012/13</p></td><td><p>2013/14</p></td></tr><tr><td><p>Research Councils and Innovate UK</p></td><td><p>0.1</p></td><td><p>0.2</p></td><td><p>0.3</p></td><td><p>0.3</p></td><td><p>0.4</p></td></tr></tbody></table><p> </p><p> </p><p> </p>
answering member constituency Mid Norfolk more like this
answering member printed George Freeman remove filter
grouped question UIN 225706 more like this
question first answered
less than 2015-03-04T17:25:17.467Zmore like thismore than 2015-03-04T17:25:17.467Z
answering member
4020
label Biography information for George Freeman more like this
tabling member
4026
label Biography information for Liz Kendall more like this
224163
registered interest false more like this
date less than 2015-02-27more like thismore than 2015-02-27
answering body
Department of Health more like this
answering dept id 17 more like this
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Epilepsy more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, how much money has been spent on the prescription of drugs to manage epilepsy in the NHS in each of the last five years. more like this
tabling member constituency Leicester West more like this
tabling member printed
Liz Kendall more like this
uin 225701 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2015-03-04more like thismore than 2015-03-04
answer text <p>Information on the cost of medicines to treat epilepsy is shown in the table.</p><p> </p><p> </p><p> </p><table><tbody><tr><td colspan="3"><p>Net Ingredient Cost of medicines dispensed in England to treat epilepsy, as defined by British National Formulary (BNF) Section 4.8.1 <em>Control of the epilepsies</em> and 4.8.2 <em>Drugs used in status epilepticus</em>.</p></td></tr><tr><td><p> </p></td><td><p>Primary care cost (£)</p></td><td><p>Secondary care cost (£)</p></td></tr><tr><td><p>2014/15 Q1 only</p></td><td><p>117,954,639</p></td><td><p>8,972,447</p></td></tr><tr><td><p>2013/14</p></td><td><p>455,561,100</p></td><td><p>33,557,584</p></td></tr><tr><td><p>2012/13</p></td><td><p>397,626,888</p></td><td><p>29,691,830</p></td></tr><tr><td><p>2011/12</p></td><td><p>382,640,431</p></td><td><p>27,282,775</p></td></tr><tr><td><p>2010/11</p></td><td><p>346,221,736</p></td><td><p>25,390,620</p></td></tr><tr><td><p>2009/10</p></td><td><p>304,583,390</p></td><td><p>23,954,258</p></td></tr></tbody></table><p> </p><p><em>Source: </em></p><p> </p><p>Prescription Cost Analysis (PCA) provided by the Health and Social Care Information Centre (primary care)</p><p> </p><p>Hospital Pharmacy Audit Index (HPAI) provided by IMS Health (secondary care)</p><p> </p><p><em> </em></p><p> </p><p><em>Notes:</em></p><p> </p><p>Net Ingredient Cost (NIC)</p><p> </p><p>NIC is the basic cost of a drug. It does not take account of discounts, dispensing costs, fees or prescription charges income.</p><p> </p><p>BNF Classifications</p><p> </p><p>The PCA system uses the therapeutic classifications defined in the BNF. Information on why a drug is prescribed is not available in this dataset. Since drugs can be prescribed to treat more than one condition, it may not be possible to separate the different conditions for which a drug may have been prescribed.</p><p> </p><p> </p><p> </p>
answering member constituency Mid Norfolk more like this
answering member printed George Freeman remove filter
question first answered
less than 2015-03-04T17:27:59.743Zmore like thismore than 2015-03-04T17:27:59.743Z
answering member
4020
label Biography information for George Freeman more like this
tabling member
4026
label Biography information for Liz Kendall more like this
224164
registered interest false more like this
date less than 2015-02-27more like thismore than 2015-02-27
answering body
Department of Health more like this
answering dept id 17 more like this
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Kidneys: Research more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, what proportion of overall health research funding was invested in renal research in each year from 2008; and what plans he has to increase funding for such research in the next five years. more like this
tabling member constituency Stretford and Urmston more like this
tabling member printed
Kate Green more like this
uin 225683 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2015-03-05more like thismore than 2015-03-05
answer text <p>From 2008-09, spend on research funded directly by the National Institute for Health Research (NIHR) has been categorised by Health Research Classification System health categories. NIHR expenditure on research infrastructure and systems where spend cannot be attributed to health categories is excluded. The following table shows NIHR spend in the health category ‘renal and urogenital’ as a proportion of total categorised spend and as a proportion of total revenue expenditure.</p><p> </p><p> </p><p> </p><table><tbody><tr><td><p>Year</p></td><td><p>Categorised</p><p>%</p></td><td><p>Total revenue</p><p>%</p></td></tr><tr><td><p>2008/09</p></td><td><p>1.3</p></td><td><p>0.5</p></td></tr><tr><td><p>2009/10</p></td><td><p>1.7</p></td><td><p>1.0</p></td></tr><tr><td><p>2010/11</p></td><td><p>1.6</p></td><td><p>1.0</p></td></tr><tr><td><p>2011/12</p></td><td><p>1.7</p></td><td><p>1.1</p></td></tr><tr><td><p>2012/13</p></td><td><p>2.0</p></td><td><p>1.5</p></td></tr><tr><td><p>2013/14</p></td><td><p>2.3</p></td><td><p>1.7</p></td></tr></tbody></table><p> </p><p> </p><p> </p><p>The usual practice of the NIHR is not to ring-fence funds for expenditure on particular topics: research proposals in all areas compete for the funding available.</p><p> </p><p>The NIHR welcomes funding applications for research into any aspect of human health, including renal disease and care. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money and scientific quality. In all disease areas, the amount of NIHR funding depends on the volume and quality of scientific activity.</p><p> </p>
answering member constituency Mid Norfolk more like this
answering member printed George Freeman remove filter
question first answered
less than 2015-03-05T11:44:04.637Zmore like thismore than 2015-03-05T11:44:04.637Z
answering member
4020
label Biography information for George Freeman more like this
tabling member
4120
label Biography information for Kate Green more like this
223973
registered interest false more like this
date less than 2015-02-26more like thismore than 2015-02-26
answering body
Department of Health more like this
answering dept id 17 more like this
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Cancer: Drugs more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, pursuant to the Answer of 29 January 2015 to Question 221764, which representatives of the pharmaceutical industry were consulted to establish that the scoring tool used by NHS England was a fair assessment of the clinical benefits of a drug; and when that consultation took place. more like this
tabling member constituency Denton and Reddish more like this
tabling member printed
Andrew Gwynne more like this
uin 225581 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2015-03-05more like thismore than 2015-03-05
answer text <p>NHS England undertook a public consultation in 2014 on its standard operating procedures for the Cancer Drugs Fund – which included the prioritisation tool. The report of that consultation process is available at:</p><p> </p><p> </p><p> </p><p><a href="http://www.england.nhs.uk/wp-content/uploads/2014/11/cdf-consult-rep.pdf" target="_blank">www.england.nhs.uk/wp-content/uploads/2014/11/cdf-consult-rep.pdf</a></p><p> </p> more like this
answering member constituency Mid Norfolk more like this
answering member printed George Freeman remove filter
question first answered
less than 2015-03-05T11:38:31.833Zmore like thismore than 2015-03-05T11:38:31.833Z
answering member
4020
label Biography information for George Freeman more like this
tabling member
1506
label Biography information for Andrew Gwynne more like this
223994
registered interest false more like this
date less than 2015-02-26more like thismore than 2015-02-26
answering body
Department of Health more like this
answering dept id 17 more like this
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Gastrointestinal Cancer: Drugs more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, what assessment he has made of the effect of taking Regorafenib off the Cancer Drugs Fund list on the health outcomes of gastrointestinal stromal tumour cancer patients. more like this
tabling member constituency Chesterfield more like this
tabling member printed
Toby Perkins more like this
uin 225505 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2015-03-05more like thismore than 2015-03-05
answer text <p>NHS England has advised that its review of the national Cancer Drugs Fund (CDF) list will ensure that more patients will be able to access drugs that provide better outcomes for their cancers.</p><p> </p><p> </p><p> </p><p>This re-evaluation of some CDF drugs, including regorafenib (Stivarga) for the treatment of gastrointestinal stromal tumours, will mean that some patients who would have received the drugs to be removed from the list will switch to alternative CDF drugs and the remainder will be offered conventional treatments.</p><p> </p><p>NHS England has also assured the Department that no patient whose treatment is currently being funded through the Fund will have funding withdrawn, as long as it is clinically appropriate that they continue to receive that treatment. In addition, no drug will be removed from the Fund where it is the only therapy for that condition.</p><p> </p> more like this
answering member constituency Mid Norfolk more like this
answering member printed George Freeman remove filter
question first answered
less than 2015-03-05T11:41:21.68Zmore like thismore than 2015-03-05T11:41:21.68Z
answering member
4020
label Biography information for George Freeman more like this
tabling member
3952
label Biography information for Mr Toby Perkins more like this
224000
registered interest false more like this
date less than 2015-02-26more like thismore than 2015-02-26
answering body
Department of Health more like this
answering dept id 17 more like this
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Diabetes more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, what steps he is taking to ensure that the need for a medical exemption certificate has been effectively communicated to sufferers of diabetes by the NHS Business Service Authority and pharmacies. more like this
tabling member constituency Manchester, Withington more like this
tabling member printed
Mr John Leech more like this
uin 225627 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2015-03-05more like thismore than 2015-03-05
answer text <p>Information about the prescription charge exemption arrangements, including the requirement to hold valid exemption certificate to claim a medical exemption, is included on NHS Choices. Long-standing arrangements are also in place to make available to general practitioner (GP) practices leaflets to put on display for patients containing details about the exemption rules and requirements. The declaration on the prescription form that patients are required to sign to claim a medical exemption from the charge also makes clear the requirement for a certificate.</p><p> </p><p> </p><p> </p><p>Additionally, in October 2014 as part of the centralisation of the prescription exemption checking process within the NHS Business Services Authority (NHSBSA), the NHSBSA sent all English pharmacies and GP practices a supply of posters and booklets entitled ‘Claiming free prescriptions?’ to make available to patients. The poster warns patients of the consequences of claiming free prescriptions incorrectly and directs them to the booklet for more information on eligibility, which states that medical exemption certificates are valid for five years. The poster and booklet are also published on the NHSBSA website:</p><p> </p><p> </p><p> </p><p><a href="http://www.nhsbsa.nhs.uk/PrescriptionServices/4666.aspx" target="_blank">http://www.nhsbsa.nhs.uk/PrescriptionServices/4666.aspx</a>.</p><p> </p><p> </p><p> </p><p>The NHSBSA is currently planning further communications work to build on this initial activity.</p><p> </p><p> </p><p> </p><p> </p><p> </p>
answering member constituency Mid Norfolk more like this
answering member printed George Freeman remove filter
question first answered
less than 2015-03-05T11:42:56.03Zmore like thismore than 2015-03-05T11:42:56.03Z
answering member
4020
label Biography information for George Freeman more like this
tabling member
1543
label Biography information for Mr John Leech more like this
223625
registered interest false more like this
date less than 2015-02-25more like thismore than 2015-02-25
answering body
Department of Health more like this
answering dept id 17 more like this
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Dialysis Machines more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, when his Department plans for the transfer of dialysis treatment to clinical commissioning groups to take place. more like this
tabling member constituency Birmingham, Selly Oak more like this
tabling member printed
Steve McCabe more like this
uin 225442 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2015-03-03more like thismore than 2015-03-03
answer text <p>Ministers are responsible for deciding which specialised services should be commissioned by NHS England. Ministers obtain advice to inform these decisions from the Prescribed Specialised Services Advisory Group (PSSAG), a Department of Health expert committee.</p><p> </p><p> </p><p> </p><p>PSSAG considered a proposal from NHS England to transfer commissioning responsibility for renal dialysis services from NHS England to clinical commissioning groups (CCGs). PSSAG advised Ministers, that on the evidence presented to it, renal dialysis services were suitable for commissioning by CCGs and did not meet the requirements for national commissioning by NHS England.</p><p> </p><p> </p><p> </p><p>However, the proposal has since been referred back to PSSAG for reconsideration after the Department became aware that PSSAG was provided with incorrect evidence when it first considered the proposals.</p><p> </p><p> </p><p> </p><p>No further decision on the transfer of commissioning responsibility for renal dialysis services can be made until PSSAG has reconsidered the proposal and provided Ministers with its updated advice. Commissioning responsibility for these services will therefore remain with NHS England at least until 1 April 2016.</p><p> </p>
answering member constituency Mid Norfolk more like this
answering member printed George Freeman remove filter
grouped question UIN
225439 more like this
225441 more like this
question first answered
less than 2015-03-03T10:34:56.807Zmore like thismore than 2015-03-03T10:34:56.807Z
answering member
4020
label Biography information for George Freeman more like this
tabling member
298
label Biography information for Steve McCabe more like this